Role of Intra-arterial Nitroglycerin (Post Procedural, Prehemostasis) to Reduce Radial Artery Occlusion after

M K Islam1, M J Uddin, A Momen

  • 1Dr Dewan Mohammmad Karimul Islam, MD, Department of Cardiology, National Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh;

Insights

Intra-arterial nitroglycerin administered after transradial procedures significantly reduces radial artery occlusion (RAO). This intervention lowers RAO incidence compared to standard compression, preserving radial artery patency.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Interventional Cardiology

Background:

  • Transradial access (TRA) is a common approach for coronary procedures.
  • Radial artery occlusion (RAO) is a potential complication following TRA.
  • Preserving radial artery patency is crucial for future vascular access.

Purpose of the Study:

  • To evaluate the efficacy of intra-arterial nitroglycerin in preventing RAO after TRA.
  • To determine if nitroglycerin administration impacts radial artery patency post-procedure.

Main Methods:

  • A prospective observational study involving 200 patients undergoing coronary angiography or percutaneous coronary intervention via TRA.
  • Group I (102 patients) received intra-arterial nitroglycerin before sheath removal; Group II (98 patients) did not.
  • Radial artery patency was assessed using Doppler ultrasound the day after the procedure.

Main Results:

  • The overall incidence of RAO one day post-TRA was 13.5%.
  • Group I showed a significantly lower RAO incidence (8.8%) compared to Group II (18.4%, p=0.04).
  • Diabetes mellitus, prolonged hemostatic compression (>2 hours), and longer procedure times were predictors of RAO.

Conclusions:

  • Intra-arterial nitroglycerin administration at the end of transradial catheterization effectively reduces the incidence of radial artery occlusion.
  • This simple intervention can help preserve radial artery patency after coronary procedures.
  • Optimizing hemostatic techniques and considering patient comorbidities are important for minimizing RAO risk.

Related Concept Videos

Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
672
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
18
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
15
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
586
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
12
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
600